loader2
Login Open ICICI 3-in-1 Account
  • Text Size
  • Text to Speech
  • Color Contrast
  • Pause Animations

Open ICICI
3-in-1 Account

Manage your Savings, Demat and Trading Account conveniently at one place

+91

BLOG

Symbiotec Pharmalab has entered into a definitive agreement with a leading global pharma company

ICICIdirect Research 01 Oct 2026 DISCLAIMER

News: Symbiotec Pharmalab has entered into a definitive agreement with a leading global pharma company for exclusive US commercialization and distribution rights for two Dual Chamber Vial (DCV)-based injectable products, addressing an estimated US$288 million market. Symbiotec will handle development, regulatory submissions, manufacturing and supply, while the partner will lead commercialization and distribution. The agreement includes milestone payments linked to development, regulatory approval and launch, along with profit-sharing from commercialization.

View: The company had highlighted in its recent concall that the commercialization of the two DCV products is structured around milestone payments. As per management, these milestones are expected to offset the operational drag from the new facilities, which is ~₹23 crore  quarterly drag we believe ~₹90–100 crore for the full year to be covered by milestone receipts by the end of this fiscal. Beyond the near-term milestone income, we expect the commercialized DCV products to contribute meaningfully to Symbiotec’s revenues from FY28/29 onwards, providing an additional growth opportunity for the company. 

Impact: Positive

Download
ICICI Direct app

Invest, Track, and Manage your Portfolio Anytime, Anywhere

Download
ICICI Direct app

Invest, Track, and Manage your Portfolio Anytime, Anywhere